@article{178491fca7aa46028b03b02a00aecb1b,
title = "Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients",
abstract = "Nodular regenerative hyperplasia (NRH) is a poorly understood liver condition, which is increasingly recognized in thiopurine-treated patients with inflammatory bowel disease (IBD). 1 It is difficult to establish an optimal approach to NRH patients, because its manifestations are highly variable (from asymptomatic to symptoms of noncirrhotic portal hypertension [NCPH]) and the prognosis is unknown. 2 The aim of this study was to identify NRH cases in IBD patients treated with azathioprine, mercaptopurine, and/or thioguanine, and to describe its clinical course. ",
author = "Melek Simsek and Berrie Meijer and Dewkoemar Ramsoekh and Gerd Bouma and \{van der Wouden\}, Egbert-Jan and \{den Hartog\}, Bert and \{de Vries\}, \{Annemarie C\} and Frank Hoentjen and Gerard Dijkstra and \{de Boer\}, \{Sybrand Y\} and Jansen, \{Jeroen M\} and \{van der Meulen\}, \{Andrea E\} and Ruud Beukers and Brink, \{Menno A\} and Toos Steinhauser and Bas Oldenburg and Gilissen, \{Lennard P\} and Naber, \{Ton H\} and Verhagen, \{Marc A\} and \{de Boer\}, \{Nanne K H\} and Mulder, \{Chris J J\}",
note = "Funding Information: Conflicts of interest These authors disclose the following: Annemarie C. de Vries has served as a speaker, member of advisory board, or consultant for Takeda, AbbVie, Tramedico, Dr Falk, and Jansen. Frank Hoentjen has served as a speaker, member of advisory board, or consultant for MSD, Takeda, Celltrion, Teva, Sandoz, Dr Falk, and Celgene. Gerard Dijkstra has received unrestricted research grants from AbbVie and Takeda; has served as a member of the advisory board for Mundipharma and Pharmacosmos; and has received speaker fees from Takeda and Janssen. Jeroen M. Jansen has served as a speaker, member of advisory board, or consultant for AbbVie, Janssen, Ferring, Pfizer, Takeda, and MSD. Bas Oldenburg has served as a speaker, member of advisory board, or consultant for AbbVie, Ferring, Janssen, MSD, Pfizer, and Takeda. Nanne K. H. de Boer has served as a speaker for AbbVie, Takeda, and MSD; has served as consultant and principal investigator for Takeda and TEVA Pharma BV; and has received research grants from Dr. Falk and Takeda. Chris J. J. Mulder has served a principal investigator for TEVA Pharma BV. The remaining authors disclose no conflicts. Publisher Copyright: {\textcopyright} 2019 AGA Institute",
year = "2019",
month = feb,
doi = "10.1016/j.cgh.2018.05.009",
language = "English",
volume = "17",
pages = "568--570",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders",
number = "3",
}